ED drugs in "supplements" prompt recalls
This article was originally published in The Tan Sheet
Los Angeles-based Haloteco July 13 recalls Libipower Plus, a product marketed as a dietary supplement that tested positive for tadalafil in an FDA lab analysis. Brea, Calif.-based Opteron 1 Inc., doing business as Nature & Health Co., July 15 recalls products labeled as supplements including LibieXtreme, Y-4ever and Herbal Disiac in retail locations in California, Georgia, Illinois, Ohio and Texas after FDA found tadalafil and analogs of other pharmaceutical ingredients used in Rx erectile dysfunction drugs such as Cialis in the products. Nature & Health Co. also recently recalled its Libimax product (1"The Tan Sheet" May 4, 2009, In Brief)
You may also be interested in...
Nature & Health Co. announces a recall of its male enhancement formula after FDA analysis found samples of Libimax contained tadalafil, the active ingredient in Eli Lilly's Rx erectile dysfunction drug Cialis. FDA warns that tadalafil, in conjunction with nitrates found in prescription cholesterol drugs, can cause a dangerous drop in blood pressure. Brea, Calif.-based Nature & Health said April 27 the recalled product was sold in retail stores in California, Georgia, Illinois, Ohio and Texas. FDA has emphasized it will seize adulterated supplement products when firms fail to comply with recall requests (1"The Tan Sheet" July 28, 2008, p. 15)
Cosmetics Europe Talks Microplastic: ECHA Frustrations, ‘Value Judgments’ And International Trade Uncertainty
The European Chemicals Agency's microplastic restriction proposal received committee backing in 2020 without changes sought by the cosmetics industry, which faces €15bn in projected costs and scarce alternatives at present. It may come down to EU Member States to decide whether the ECHA restriction proposal is proportionate in balancing environmental goals and socio-economic impacts.
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.